Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Dragana, Vujic (16647611700)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Treatment results of childhood acute myeloid leukemia in Serbia
    (2013)
    Nada, Krstovski (29467677800)
    ;
    Milos, Kuzmanovic (6602721300)
    ;
    Dragana, Vujic (16647611700)
    ;
    Lidija, Dokmanovic (29467699700)
    ;
    Dragan, Micic (55152371100)
    ;
    Bojana, Slavkovic (6507636002)
    ;
    Dejan, Skoric (34970820800)
    ;
    Jelena, Lazic (56963809700)
    ;
    Ankica, Jovanovic (55548294400)
    ;
    Milena, Jovic (55548219100)
    ;
    Nada, Konstantinidis (6603870463)
    ;
    Gordana, Kostic (55547781600)
    ;
    Predrag, Rodic (15846736800)
    ;
    Dragana, Janic (15729368500)
    We present the results of a retrospective study of acute myeloid leukemia (AML) treatment in Serbia in the period 2000-2012. Treatment was performed in four centers, two of which were located in Belgrade, one in Nis, and one in Novi Sad. Children affected by non-acute promyelocytic leukemia (non-APL) subtypes received treatment regimens derived from protocols of Berlin Frankfurt Munster AML study group, whereas children with APL were treated according to the AIEOP/GIMEMA ATRA plus Idarubicin "AIDA" protocol. Total number of patients was 106, out of whom 48 were girls (45.3 %) and 58 boys (54.7 %); median age at diagnosis was 9.0 years (range 1 month-17.9 years). In total, 82.1 % of patients achieved complete remission after induction treatment. Twelve patients (11.3 %) died during induction, before achieving complete remission; there were nine deaths during remission (10.5 %) and 20 patients relapsed (23.2 %). Median time of follow-up was 54 months. Two patients (1.9 %) were lost to follow-up. Event-free survival was 50.3 % and overall survival was 58.9 %. © 2012 Springer-Verlag Wien.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback